APA (7th ed.) Citation

JV, P., PD, B., DT, R., RJ, B., CL, D., PR, K., . . . PW, W. (2022). Combined 70- and 80-gene signatures identify tumors with genomically luminal biology responsive to neoadjuvant endocrine therapy and are prognostic of 5-year outcome in early-stage breast cancer. Surgical oncology, 45, 101885. https://doi.org/10.1016/j.suronc.2022.101885

Chicago Style (17th ed.) Citation

JV, Pellicane, et al. "Combined 70- and 80-gene Signatures Identify Tumors with Genomically Luminal Biology Responsive to Neoadjuvant Endocrine Therapy and Are Prognostic of 5-year Outcome in Early-stage Breast Cancer." Surgical Oncology 45 (2022): 101885. https://doi.org/10.1016/j.suronc.2022.101885.

MLA (9th ed.) Citation

JV, Pellicane, et al. "Combined 70- and 80-gene Signatures Identify Tumors with Genomically Luminal Biology Responsive to Neoadjuvant Endocrine Therapy and Are Prognostic of 5-year Outcome in Early-stage Breast Cancer." Surgical Oncology, vol. 45, 2022, p. 101885, https://doi.org/10.1016/j.suronc.2022.101885.